FID-007
Broad range of cancers (e.g., breast, lung, ovarian, colon, head & neck, pancreatic)
Phase 1Active
Key Facts
Indication
Broad range of cancers (e.g., breast, lung, ovarian, colon, head & neck, pancreatic)
Phase
Phase 1
Status
Active
Company
About Fulgent Pharma
Fulgent Pharma is a private, clinical-stage biotech founded in 2011, specializing in oncology drug development through a proprietary polymer-based nanoencapsulation platform. Its lead asset, FID-007, is a nanoencapsulated paclitaxel in clinical trials designed to offer improved efficacy and reduced toxicity compared to standard chemotherapy. The company's strategy involves repurposing existing chemotherapies and developing new drug candidates, with key partnerships including the University of Southern California and Moffitt Cancer Center. As a pre-revenue entity, its near-term value drivers are clinical data readouts and pipeline advancement.
View full company profile